Emyria’s Managing Director, Dr. Michael Winlo
Highlights:
• Tattarang to invest $5m in Emyria via share placement
• Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family.
• Funds raised will be used to accelerate synthetic cannabinoid registration programs with the TGA and FDA, and advance Emyria’s novel MDMA-analogue development program with the University of Western Australia.
• For further information please visit tattarang.com
Emyria Limited (ASX: EMD) (Emyria or the Company), data-backed drug development and care delivery company, is pleased to announce a successful $5 million share placement to strategic investor Tattarang (Placement).
Tattarang Chief Investment Officer John Hartman remarked on the investment saying, “Emyria’s investment in industry-leading data collection at the front-line of care will allow it to innovate faster and help bring new treatments to those who need them, faster and more cost-effectively.
“We believe evidence-based, and properly registered, medicinal cannabis and novel psychedelic treatments have massive growth potential across global healthcare jurisdictions.
Emyria’s data-driven approach positions it strongly to lead the accelerated development and registration of new treatment options that can potentially benefit millions of patients.”
Emyria’s Managing Director, Dr. Michael Winlo, said: “We are delighted to receive Tattarang’s strong support with this placement.
Tattarang shares our long-term vision to accelerate the development and registration of medicines that can transform the lives of millions of people around the world living with conditions for which current therapies are either ineffective, cause unwanted side effects, or are yet to be created.
Emyria is the only ASX-listed company that controls patient-treating clinics and a clinical-trial-grade data system and uses these assets to accelerate the development and registration of new drugs, digital technologies, and care models.
Our current leading programs cover synthetic cannabinoid-based pharmaceuticals, MDMA-assisted therapy, and novel psychedelic drug development. We are very pleased to welcome Tattarang to be part of this next phase of growth.”
This article was sourced from a media release sent by Medianet
